US · COYA · BIOTECHNOLOGY
Coya Therapeutics, Inc. (COYA) intrinsic value and stock valuation
$2.95as of 2026-11-21 · Mkt cap 82.85M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Coya Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values COYA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COYA’s statements →
Coya Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.95M | $3.55M | $6M | $0.00 | $0.00 |
| Operating income | -$-20.27M | -$-17.25M | -$-7.9M | -$-9.81M | -$-4.87M |
| Net income | -$-21.23M | -$-14.88M | -$-7.99M | -$-12.24M | -$-4.89M |
| EPSd | -$-1.27M | -$-976.38K | -$-786.42K | -$-1.23M | -$-740.91K |
| Operating cash flow | -$-10.74M | -$-10.29M | -$-11.19M | -$-7.24M | -$-3.9M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$-140K |
| Free cash flow | -$-10.74M | -$-10.29M | -$-11.19M | -$-7.24M | -$-4.04M |
| Total assets | $50M | $44.4M | $41.3M | $8.4M | $4.79M |
| Total debt | $0.00 | $0.00 | $0.00 | $13M | $0.00 |
| Net debt | -$-46.82M | -$-38.34M | -$-32.63M | $7.03M | -$-4.34M |
| Total equity | $43M | $39.6M | $35.6M | -$-8.39M | $3.64M |
| Cash and short-term investments | $46.8M | $38.3M | $32.6M | $5.93M | $4.34M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.95M | $3.55M | $6M | $0.00 | $0.00 |
| Cost of revenue | $30K | $11.9M | $5.5M | $4.41M | $0.00 |
| Gross profit | $7.92M | -$-8.31M | $500K | -$-4.41M | $0.00 |
| Research and development expenses | $16.7M | $11.9M | $6.04M | $4.94M | $2.54M |
| Selling, general and administrative expenses | $11.5M | $8.89M | $7.83M | $4.85M | $2.31M |
| Other expenses | $0.00 | -$-11.84M | -$-5.47M | -$-4.39M | $20K |
| Operating expenses | $28.2M | $8.94M | $8.4M | $5.4M | $4.87M |
| Cost and expenses | $28.2M | $20.8M | $13.9M | $9.81M | $4.87M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $30K | $30K | $30K | $30K | $20K |
| Ebitda | -$-21.2M | -$-17.2M | -$-7.33M | -$-9.26M | -$-4.88M |
| Operating income | -$-20.27M | -$-17.25M | -$-7.9M | -$-9.81M | -$-4.87M |
| Total other income/expenses, net | -$-960K | $1.65M | $640K | -$-2.43M | -$-20K |
| Income before tax | -$-21.22M | -$-15.6M | -$-7.26M | -$-12.24M | -$-4.89M |
| Income tax expense | $0.00 | -$-720K | $720K | $0.00 | $0.00 |
| Net income | -$-21.23M | -$-14.88M | -$-7.99M | -$-12.24M | -$-4.89M |
| Weighted average shares outstanding | $16.7M | $15.2M | $10.2M | $9.95M | $6.6M |
| Weighted average diluted shares outstanding | $16.7M | $15.2M | $10.2M | $9.95M | $6.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $46.8M | $38.3M | $32.6M | $5.93M | $4.34M |
| Net receivables | $0.00 | $730K | $7.5M | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $49.9M | $44.3M | $41.2M | $7.18M | $4.58M |
| Property, plant and equipment, net | $10K | $40K | $70K | $90K | $120K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $10K | $40K | $70K | $1.21M | $210K |
| Total assets | $50M | $44.4M | $41.3M | $8.4M | $4.79M |
| Accounts payable | $1.06M | $1.59M | $1.16M | $1.82M | $860K |
| Short-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $1.2M | $850K | $920K | $0.00 | $0.00 |
| Total current liabilities | $5.87M | $3.82M | $5.05M | $3.82M | $1.15M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $13M | $0.00 |
| Deferred revenue, non-current | $1.05M | $950K | $570K | $0.00 | $0.00 |
| Total non-current liabilities | $1.05M | $950K | $570K | $13M | $0.00 |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $6.92M | $4.77M | $5.63M | $16.8M | $1.15M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-61.96M | -$-40.74M | -$-25.86M | -$-17.87M | -$-5.62M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $43M | $39.6M | $35.6M | -$-8.39M | $3.64M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $13M | $0.00 |
| Net debt | -$-46.82M | -$-38.34M | -$-32.63M | $7.03M | -$-4.34M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-21.23M | -$-14.88M | -$-7.99M | -$-12.24M | -$-4.89M |
| Depreciation and amortization | $30K | $30K | $30K | $30K | $20K |
| Stock-based compensation | $4.29M | $2.66M | $870K | $210K | $230K |
| Change in working capital | $3.88M | $1.88M | -$-4.64M | $750K | $740K |
| Accounts receivable | $0.00 | $7.5M | -$-7.5M | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-530K | $480K | $300K | $850K | $670K |
| Net cash provided by operating activities | -$-10.74M | -$-10.29M | -$-11.19M | -$-7.24M | -$-3.9M |
| Investments in property, plant and equipment | -$-1.16M | $0.00 | $0.00 | $0.00 | -$-140K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-1.16M | -$-30K | -$-540K | -$-530K | -$-140K |
| Common stock issued | $20.4M | $14M | $38.3M | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $20.4M | $16M | $38.4M | $9.36M | -$-340K |
| Net change in cash | $8.48M | $5.71M | $26.7M | $1.59M | -$-4.38M |
| Cash at end of period | $46.8M | $38.3M | $32.6M | $5.93M | $4.34M |
| Operating cash flow | -$-10.74M | -$-10.29M | -$-11.19M | -$-7.24M | -$-3.9M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$-140K |
| Free cash flow | -$-10.74M | -$-10.29M | -$-11.19M | -$-7.24M | -$-4.04M |
Line items
Line items
Line items
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
- CEO
- Arun Swaminathan
- Employees
- 8
- Beta
- 0.60
Explore
Frequently asked questions
What is the intrinsic value of Coya Therapeutics, Inc. (COYA)?
Coya Therapeutics, Inc. (COYA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is COYA undervalued?
COYA trades at a price of $2.95 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.